Aligos Therapeutics regains Nasdaq minimum bid price compliance

Aligos Therapeutics, Inc.

Received Nasdaq letter on Sept 3, 2024 confirming compliance with Minimum Bid Price Requirement.
Previous deficiency letter was dated Sept 5, 2023; stock had closed below $1.00 for 30 consecutive days.
Compliance achieved under Nasdaq Listing Rules 5450(a)(1) and 5550(a)(2); matter is closed.
No additional financial or operational details provided in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.